By a News Reporter-Staff News Editor at Pharma Business Week Baxter International Inc. (NYSE:BAX) announced the United States Food and Drug Administration (FDA) has approved PHOXILLUM Renal Replacement Solutions (BK4/2.5 and B22K4/0) as replacement ... Pharmacy Choice, 3 weeks ago
Baxter receives FDA approval for phoxillum solution for electrolyte management during CRRT - Pharmacist.com, 1 month ago
1/27/15 - Baxter Gets FDA Approval for PHOXILLUM Solution [Professional Services Close - Up] - Pharmacy Choice, 1 month ago
3 images for "continuous renal replacement therapy"
Some metabolic issues should not be neglected when using citrate for continuous renal replacement therapy!
We read with great interest the paper by Schilder and colleagues on citrate anticoagulation versus systemic heparinisation (CASH) [ 1 ] and its related commentary [ 2 ], but would like to comment on two important metabolic issues. First, ...Critical Care, 2 weeks ago
General Please address all your queries or problem reports to the Pay-per-View Customer Service at firstname.lastname@example.org referring to PPV or PPV account. 1. All payments are by credit card only. The transaction is secure: standard-procedure SSL or ...Sexual Development, 1 month ago
Feb. 16, 2015 12:15 PM ET | About: Medgenics (MDGN) by: Subscribers to SA PRO had an early look at this article. Learn more about PRO » Summary MDGN-201 EPO Clinical Trial Continues to Show Promising Results. One Patient Has Now Been ...Seeking Alpha, 1 week ago Medgenics Reports Fourth Quarter and Full Year 2014 Financial Results Benzinga.com, 2 weeks ago Ipsen: Sales in the Fourth Quarter and Full Year 2014 MoneyShow.com, 3 weeks ago
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary ...Individual.com, 3 days ago Rockwell Medical Schedules Fourth Quarter Earnings Call Individual.com, 6 days ago FDA approves Natpara for injection to control hypocalcemia in patients with hypoparathyroidism Pharmaceutical Business Review, 1 month ago FDA Approves Rockwell Medicall's Triferic For Iron Replacement And Maintenance Of Hemoglobin In Hemodialysis Patient BioSpace, 1 month ago
Hidron AI, Edwards JR, Patel J, et al . NHSN annual update: antimicrobialresistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease ...General Medicine eJournal, 1 week ago
NEW ORLEANS — Home dialysis continues to gain recognition as a safe and practical alternative to in-center dialysis for patients who need renal replacement therapy. However, appropriate training and competency in its delivery is lacking, according ...Dermatology Online Journal, 3 weeks ago
Comment · print · T T T+· T- TOPICS While legendary cartoonist R.K. Laxman continues to be in a critical condition, he has been taken off ventilator support, which brings hope of a recovery, said medical sources on Friday. Citing a ...The Hindu, 1 month ago Veteran cartoonist RK Laxman's health improves DNA India, 1 month ago R.K.Laxmantaken off ventilator support The Hindu, 1 month ago
[January 16, 2015] Diaverum, one of the world's leading renal care providers, today announced the acquisition of Nefros Asia in Kazakhstan with nine kidney centres across the country. The centres will shortly begin the ...TMC Net, 1 month ago
Celldex Therapeutics, Inc. And Bristol-Myers Squibb Company Announce Initiation Of Phase 1/2 Combination Study Of Varlilumab And Opdivo® In Advanced Refractory Solid Tumors
HAMPTON, N.J., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) and Bristol Myers-Squibb (NYSE:BMY) today announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational ...BioSpace, 1 month ago Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) in Advanced Refractory Solid Tumors Wall Street Business Network, 1 month ago Bristol Myers Squibb : Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo® in Advanced Refractory Solid Tumors 4 Traders, 1 month ago SHIRE PLC - 10-K - : Management's discussion and analysis of financial condition and results of operations Pharmacy Choice, 4 days ago
More from: SearchBug, Town Hall...and 20 other sources
on your WebpageAdd Widget >Get your members hooked!